Neoadjuvant targeted therapy for resectable EGFR-mutant non-small cell lung cancer: Current status and future considerations

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) targeted therapy has become the standard of care for patients with EGFR-mutated metastatic non-small cell lung cancer (NSCLC) on the basis of improved prognosis and reduced toxicities compared with chemotherapy. In view of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wenliang, Ren, Siying, Xiao, Ying, Yang, Lulu, Zeng, Chao, Hu, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712740/
https://www.ncbi.nlm.nih.gov/pubmed/36467102
http://dx.doi.org/10.3389/fphar.2022.1036334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712740/
https://www.ncbi.nlm.nih.gov/pubmed/36467102
http://dx.doi.org/10.3389/fphar.2022.1036334

Ejemplares similares